Coronavirus: Glenmark gets India approval for favipiravir as COVID-19 treatment

Tablets of Avigan (generic name : Favipiravir), a drug approved as an anti-influenza drug in Japan and developed by drug maker Toyama Chemical Co, a subsidiary of Fujifilm Holdings Co. (File photo: Reuters)

Glenmark Pharmaceuticals Ltd has received Indian regulatory approval to make and sell oral antiviral drug favipiravir for treating mild-to-moderate COVID-19 infections in the country, it said on Friday.

The Mumbai-based company said the approval was part of India’s accelerated approval process and the drug was meant for “restricted emergency use,” meaning patients must sign their consent before being treated by the drug.

For more coronavirus news, visit our dedicated page.

Favipiravir is also undergoing trials in other countries to test its efficacy as a COVID-19 treatment.

Japan’s Fujifilm Holdings Corp, which makes favipiravir under the brand name Avigan, said last week its research on the drug as a potential COVID-19 treatment may drag on until July.

Read more:

Coronavirus: Europe COVID-19 cases rise above 2.5 million

Iran reports over 2,300 new cases of coronavirus infections, as death toll tops 9,500

Coronavirus: UK to review two-meter social distancing rule for England

Drugmakers across the world have been rushing to develop a treatment or vaccine for the novel coronavirus, which has infected 8.5 million people globally, killing more than 453,000, according to a Reuters tally.

India, the fourth-worst hit country, reported a record daily jump in the number of coronavirus cases on Friday, and the death toll reached 12,573.

For all the latest headlines follow our Google News channel online or via the app.

Read also: The life-saving coronavirus drug: What is dexamethasone & how can it beat COVID-19?

The approval for favipiravir in India, which Glenmark plans to sell as “FabiFlu”, was granted based on “evaluation of data,” the company said in a brief statement to stock exchanges.

The company plans to provide more details in a press briefing on Saturday, it added.

Glenmark began a late-stage trial of favipiravir on COVID-19 patients last month. It is also separately testing a combination of favipiravir and umifenovir, another anti-viral drug, as a potential COVID-19 treatment.

SHOW MORE
Last Update: Saturday, 20 June 2020 KSA 20:35 - GMT 17:35
Top